Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Shen, Jun ^a   Liu, Ziling ^b   Todd, Nevins W ^a   Zhang, Howard ^a   Liao, Jipei ^a   Yu, Lei ^a   Guarnera, Maria A ^a   Li, Ruiyun ^a   Cai, Ling ^a   Zhan, Min ^a   Jiang, Feng ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; TUMOR MARKER;

ADULT; AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; GENE EXPRESSION; GENETIC MARKER; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG FIBROSIS; LUNG GRANULOMA; LUNG NODULE; LUNG SARCOIDOSIS; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PREDICTION; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR DIFFERENTIATION; AREA UNDER THE CURVE; BIOSYNTHESIS; BLOOD; GENETICS; LUNG TUMOR; MIDDLE AGED; NONPARAMETRIC TEST; REPRODUCIBILITY; SMOKING; STATISTICAL MODEL;

AGED; AREA UNDER CURVE; FEMALE; HUMANS; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; ROC CURVE; SMOKING; SOLITARY PULMONARY NODULE; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 80052027132     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-374     Document Type: Article

References (52)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96. 10.3322/CA.2007.0010, 18287387.
2. Flehinger BJ, Melamed MR, Zaman MB, Heelan RT, Perchick WB, Martini N. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Johns Hopkins study. Am Rev Respir Dis 1984, 130:549-554.
3. Hirsch FR, Franklin WA, Gazdar AF, Bunn PA. Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. Clin Cancer Res 2001, 7:5-22.
4. Minna JD, Roth JA, Gazdar AF. Focus on lung cancer. Cancer Cell 2002, 1:49-52. 10.1016/S1535-6108(02)00027-2, 12086887.
5. Henschke CI, Boffetta P, Gorlova O, Yip R, Delancey JO, Foy M. Assessment of lung-cancer mortality reduction from CT Screening. Lung Cancer 2011, 71:328-332. 10.1016/j.lungcan.2010.10.025, 21168236.
6. Smith RA, Cokkinides V, Eyre HJ. Cancer screening in the United States, 2007: a review of current guidelines, practices, and prospects. CA Cancer J Clin 2007, 57:90-104. 10.3322/canjclin.57.2.90, 17392386.
7. National Lung Screening Trial Research Team The National Lung Screening Trial: Overview and Study Design. Radiology 2011, 2:243-253. National Lung Screening Trial Research Team.
8. The National Lung Screening Trial Research Team Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. N Engl J Med 2011, 395-409. The National Lung Screening Trial Research Team.
9. Ost D, Fein AM, Feinsilver SH. Clinical practice. The solitary pulmonary nodule. N Engl J Med 2003, 348:2535-2542. 10.1056/NEJMcp012290, 12815140.
10. Kahn N, Kuner R, Eberhardt R, Meister M, Muley T, Winteroll S, Schnabel PA, Ishizaka A, Herth FJ, Poustka A, Sultmann H, Hoffmann H. Gene expression analysis of endobronchial epithelial lining fluid in the evaluation of indeterminate pulmonary nodules. J Thorac Cardiovasc Surg 2009, 138:474-479. 10.1016/j.jtcvs.2009.04.024, 19619798.
11. Wahidi MM, Herth FJ, Ernst A. State of the art: interventional pulmonology. Chest 2007, 131:261-274. 10.1378/chest.06-0975, 17218585.
12. Beigelman-Aubry C, Hill C, Grenier PA. Management of an incidentally discovered pulmonary nodule. Eur Radiol 2007, 17:449-466. 10.1007/s00330-006-0399-7, 17021707.
13. Ostrow KL, Hoque MO, Loyo M, Brait M, Greenberg A, Siegfried JM, Grandis JR, Gaither Davis A, Bigbee WL, Rom W, Sidransky D. Molecular analysis of plasma DNA for the early detection of lung cancer by quantitative methylation-specific PCR. Clin Cancer Res 2010, 16:3463-3472. 10.1158/1078-0432.CCR-09-3304, 2899894, 20592015.
14. Belinsky SA, Schiller JH, Stidley CA. DNA methylation biomarkers to assess therapy and chemoprevention for non-small cell lung cancer. Nutr Rev 2008, 66(Suppl 1):24-26.
15. Subramanian J, Simon R. Gene expression-based prognostic signatures in lung cancer: ready for clinical use?. J Natl Cancer Inst 2010, 102:464-474. 10.1093/jnci/djq025, 2902824, 20233996.
16. Ambros V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell 2003, 6:673-676.
17. Galasso M, Elena Sana M, Volinia S. Non-coding RNAs: a key to future personalized molecular therapy?. Genome Med 2010, 2:12. 10.1186/gm133, 2847703, 20236487.
18. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838. 10.1038/nature03702, 15944708.
19. Foekens JA, Sieuwerts AM, Smid M, Look MP, de Weerd V, Boersma AW, Klijn JG, Wiemer EA, Martens JW. Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci USA 2008, 105:13021-13026. 10.1073/pnas.0803304105, 2529088, 18755890.
20. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM, Harris CC. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9:189-198. 10.1016/j.ccr.2006.01.025, 16530703.
21. Patnaik SK, Kannisto E, Knudsen S, Yendamuri S. Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. Cancer Res 2010, 70:36-45. 10.1158/0008-5472.CAN-09-3153, 20028859.
22. Lebanony D, Benjamin H, Gilad S, Ezagouri M, Dov A, Ashkenazi K, Gefen N, Izraeli S, Rechavi G, Pass H, Nonaka D, Li J, Spector Y, Rosenfeld N, Chajut A, Cohen D, Aharonov R, Mansukhani M. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol 2009, 27:2030-2037. 10.1200/JCO.2008.19.4134, 19273703.
23. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008, 105:10513-10518. 10.1073/pnas.0804549105, 2492472, 18663219.
24. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang CY. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008, 18:997-1006. 10.1038/cr.2008.282, 18766170.
25. Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, Chen Y, Xu L, Zen K, Zhang C, Shen H. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 2010, 28:1721-1726. 10.1200/JCO.2009.24.9342, 20194856.
26. Yu L, Todd NW, Xing L, Xie Y, Zhang H, Liu Z, Jiang F. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer 2010, 127:2870-2878. 10.1002/ijc.25289, 21351266.
27. Xing L, Todd NW, Yu L, Fang H, Jiang F. Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers. Mod Pathol 2010, 8:1157-1164.
28. Xie Y, Todd NW, Liu Z, Zhan M, Fang H, Peng H, Jiang F. Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer 2010, 67:170-176. 10.1016/j.lungcan.2009.04.004, 2846426, 19446359.
29. Shen J, Todd NW, Zhang H, Yu L, Lingxiao X, Mei Y, Jiang F. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest 2011, 91:579-587. 10.1038/labinvest.2010.194, 3130190, 21116241.
30. Davoren PA, McNeill RE, Lowery AJ, Kerin MJ, Miller N. Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer. BMC Mol Biol 2008, 9:76. 10.1186/1471-2199-9-76, 2533012, 18718003.
31. Pepe MS. Study design and hypothesis testing. The Statistical Evaluation of Medical Tests for Classification and Prediction 2003, 214-251. New York: Oxford University Press, Pepe MS.
32. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 2008, 100:1432-1438. 10.1093/jnci/djn326, 2567415, 18840817.
33. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005, 65:6029-6033. 10.1158/0008-5472.CAN-05-0137, 16024602.
34. Pezzolesi M G, Platzer P, Waite KA, Eng C. Differential expression of PTEN-targeting microRNAs miR-19a and miR-21 in Cowden syndrome. Am J Hum Genet 2008, 82:1141-1149. 10.1016/j.ajhg.2008.04.005, 2427229, 18460397.
35. Zhu S, Si ML, Wu H, Mo YY. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 2007, 282:14328-14336. 10.1074/jbc.M611393200, 17363372.
36. du Rieu MC, Torrisani J, Selves J, Al Saati T, Souque A, Dufresne M, Tsongalis GJ, Suriawinata AA, Carrère N, Buscail L, Cordelier P. MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. Clin Chem 2010, 56:603-612. 10.1373/clinchem.2009.137364, 20093556.
37. Zhang HL, Yang LF, Zhu Y, Yao XD, Zhang SL, Dai B, Zhu YP, Shen YJ, Shi GH, Ye DW. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 2011, 71:326-331. 10.1002/pros.21246, 20842666.
38. Oh HK, Tan AL, Das K, Ooi CH, Deng NT, Tan IB, Beillard E, Lee J, Ramnarayanan K, Rha SY, Palanisamy N, Voorhoeve PM, Tan P. Genomic loss of miR-486 regulates tumor progression and the OLFM4 anti-apoptotic factor in gastric cancer. Clin Cancer Res 2011, 17:2657-2667. 10.1158/1078-0432.CCR-10-3152, 21415212.
39. Mees ST, Mardin WA, Sielker S, Willscher E, Senninger N, Schleicher C, Colombo-Benkmann M, Haier J. Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas. Ann Surg Oncol 2009, 16:2339-2350. 10.1245/s10434-009-0531-4, 19475450.
40. Bansal A, Lee IH, Hong X, Anand V, Mathur SC, Gaddam S, Rastogi A, Wani SB, Gupta N, Visvanathan M, Sharma P, Christenson LK. Feasibility of microRNAs as biomarkers for Barrett's esophagus progression: a pilot cross-sectional, phase 2 biomarker study. Am J Gastroenterol 2011, 106:1055-1063. 10.1038/ajg.2011.37, 21407181.
41. Huang X, Ding L, Bennewith KL, Tong RT, Welford SM, Ang KK, Story M, Le QT, Giaccia AJ. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell 2009, 6:856-867.
42. Scapoli L, Palmieri A, Lo Muzio L, Pezzetti F, Rubini C, Girardi A, Farinella F, Mazzotta M, Carinci F. MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression. Int J Immunopathol Pharmacol 2010, 23:1229-1234.
43. Puisségur MP, Mazure NM, Bertero T, Pradelli L, Grosso S, Robbe-Sermesant K, Maurin T, Lebrigand K, Cardinaud B, Hofman V, Fourre S, Magnone V, Ricci JE, Pouysségur J, Gounon P, Hofman P, Barbry P, Mari B. miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Cell Death Differ 2011, 18:465-478. 10.1038/cdd.2010.119, 20885442.
44. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS, Harris AL. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008, 5:672-675.
45. Wang J, Chen J, Chang P, LeBlanc A, Li D, Abbruzzesse JL, Frazier ML, Killary AM, Sen S. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila) 2009, 2:807-813.
46. Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 2004, 4:707-717. 10.1038/nrc1432, 15343277.
47. Guillaud M, le Riche JC, Dawe C, Korbelik J, Coldman A, Wistuba II, Park IW, Gazdar A, Lam S, MacAulay CE. Nuclear morphometry as a biomarker for bronchial intraepithelial neoplasia: correlation with genetic damage and cancer development. Cytometry A 2005, 63:34-40.
48. Schwartz AG, Ruckdeschel JC. Familial lung cancer: genetic susceptibility and relationship to chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 173:16-22. 10.1164/rccm.200502-235PP, 2662980, 16141445.
49. Roth C, Kasimir-Bauer S, Pantel K, Schwarzenbach H. Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer. Mol Oncol 2011, 5:281-291. 10.1016/j.molonc.2011.02.002, 21398193.
50. Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F, Calabrò E, Croce CM, Pastorino U, Sozzi G. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci USA 2011, 108:3713-3718. 10.1073/pnas.1100048108, 21300873.
51. Foss KM, Sima C, Ugolini D, Neri M, Allen KE, Weiss GJ. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer. J Thorac Oncol 2011, 6:482-488. 10.1097/JTO.0b013e318208c785, 21258252.
52. Jiang F, Todd NW, Qiu Q, Liu Z, Katz RL, Stass SA. Combined genetic analysis of sputum and computed tomography for noninvasive diagnosis of non-small-cell lung cancer. Lung Cancer 2009, 66:58-63. 10.1016/j.lungcan.2009.01.004, 19181417.